Here, we evaluated the effect of the enzyme that degrades adenosine (ADA) on adenosine-dependent invasive capacity of GSCs mediated by HIF-2α under hypoxia conditions and MRPs-mediated chemoresistance, as a new strategy proposed to revert GBM recurrence. The gene discussed is EPAS1; the disease is glioblastoma.